Denali Therapeutics DNLI Insider Ownership

Updated Oct 10, 2026

Over the past year, DNLI insiders sold $1.3 million of stock (71.13K shares) on the open market and bought none.

• A count shows 4 insiders selling DNLI stock on the open market over the past 12 months and none buying.
• Ryan J. Watts (President and CEO) was DNLI's largest open-market seller in the past 12 months, with $580,767 of sales (35.2K shares); the latest was on January 6, 2026.
• The latest open-market trade on record is a sale of 1.65K shares for $36,868 by Peter Scott Chin (Chief Medical Officer) on September 4, 2026.
• Apart from open-market trades, DNLI insiders received 166.52K shares in stock awards and gave away 32.22K shares as gifts in the past 12 months.
• Business Quant data puts insider holdings in DNLI at 10.86Mn shares across insiders' latest Form 4 filings, up 1.47% from 10.71Mn shares at the end of Q2 2026 and up 2.70% from 10.58Mn shares at the end of Q3 2025.
• Direct holdings account for 3.18Mn shares (29.24%) of DNLI's insider total, and indirect holdings through trusts, partnerships and family members for 7.69Mn shares (70.76%).
• Business Quant counts 14 insiders with holdings in Denali Therapeutics stock, among the officers, directors and 10% owners who have filed a Form 4 in the past two years.
• DNLI's largest insider holders by reported holdings are Baker Bros. Advisors LP (Director, 3.42Mn shares), Ryan J. Watts (President and CEO, 2.42Mn shares) and Marc Tessier-Lavigne (Director, 2.12Mn shares).
• The largest insider, Baker Bros. Advisors LP, holds 31.50% of DNLI's insider total.
• Institutions accounted for 83.39% of DNLI's outstanding shares in Q2 2026, insiders about 5.80% per their latest Form 4 filings, and other investors, including the public, about 10.81%.
• Over the past 12 months, 11 insiders reported transactions in Denali Therapeutics stock in 19 Form 4 filings.
• This summary of Denali Therapeutics insider activity covers Form 4 filings through September 9, 2026.